China’s healthcare market is increasingly attracting interest from Western and Chinese investment funds.
Eight Roads Ventures, the proprietary investment arm of Fidelity International, recently launched a $250 million healthcare fund focused on Chinese therapeutics, healthcare services, healthcare IT, and medical technology. Reflecting the fund’s bullish view on the boom in drug innovation in China, about 40 percent of its capital will be allocated to therapeutics.
Ping An Ventures, China’s largest insurer, is aiming to raise $1.3 billion soon for two new healthcare funds with a focus on growing medical companies and pre-IPO investments. The firm plans to raise a dollar fund of $300 million to $500 million and a RMB fund worth about $650 million to $810 million. The firm is also planning to list two entities on Hong Kong’s stock exchange this year: Ping An Good Doctor, an online medical platform that allows users to consult doctors for diagnosis; and Ping An Healthcare Technology, a medical data collection and analysis business.
In addition, Shanghai-based venture firm C-Bridge Capital is aiming to raise $650 million for investments in Chinese healthcare. The new fund will bring C-Bridge’s assets under management to $1.35 billion. C-Bridge’s portfolio includes China’s leading private hematology and oncology hospital group, biotech companies, pharmaceutical distribution companies, as well as local device companies in China.